Up to 35 adult patients with metastatic melanoma will be enrolled in this study with a target
enrollment of 30 evaluable subjects who complete the baseline and an approximately 3 week FDG
PET/CT scans, they may also complete an FDG PET/CT after 10 weeks of pembrolizumab therapy.
Subjects may also be a part of the Penn Melanoma Tissue Collection Program and then will be
asked to have one additional tumor biopsy and one additional blood draw for the purposes of
this imaging study. Subjects who are eligible for this imaging protocol will undergo a
baseline FDG PET/CT scan as part of their clinical restaging prior to starting new therapy. A
research FDG PET/CT will take place approximately 3 weeks post-therapy and a 3rd FDG PET/CT
scan will be done at more than 10 weeks after starting pembrolizumab, this scan may be done
as a clinical scan for evaluation of response or restaging after therapy, however, if it is
not ordered as a clinical scan it will be done as a research scan. Changes in FDG uptake will
be correlated with blood and tissue results from the patient's medical records and from the
data collected as part of the Penn Melanoma Tissue Collection Program and with long term
outcomes including progression free and overall survival.
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania